{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:42:14Z","timestamp":1790757734272,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.schres.2019.04.021","type":"journal-article","created":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T06:46:28Z","timestamp":1558248388000},"page":"193-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study"],"prefix":"10.1016","volume":"209","author":[{"given":"Conor W.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-4515","authenticated-orcid":false,"given":"Brian J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.schres.2019.04.021_bb0005","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.psyneuen.2012.04.001","article-title":"Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome","volume":"37","author":"Beumer","year":"2012","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.schres.2019.04.021_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-016-0001-5","article-title":"Personalized medicine for schizophrenia","volume":"3","author":"Buckley","year":"2017","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.schres.2019.04.021_bb0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11883-010-0098-3","article-title":"Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome","volume":"12","author":"Devaraj","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.04.021_bb0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2010.02.1028","article-title":"Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia","volume":"118","author":"Fan","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.04.021_bb0025","article-title":"Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ dataset","volume":"33","author":"Fond","year":"2016","journal-title":"Eur. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2019.04.021_bb0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00406-017-0847-1","article-title":"Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort","volume":"268","author":"Fond","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2019.04.021_bb0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.2018.87","article-title":"Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort","volume":"213","author":"Fond","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.04.021_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-017-0847-1","article-title":"Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort","author":"Fond","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2019.04.021_bb0045","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjmed.2006.02.031","article-title":"Metabolic syndrome and risk of cardiovascular disease: a meta-analysis","volume":"119","author":"Galassi","year":"2006","journal-title":"Am. J. Med."},{"issue":"1-2","key":"10.1016\/j.schres.2019.04.021_bb5000","doi-asserted-by":"crossref","first-page":"388-94","DOI":"10.1016\/j.schres.2015.07.047","article-title":"Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort","volume":"168","author":"Godin","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.04.021_bb0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpsychires.2017.06.008","article-title":"Predictors of rapid high weight gain in schizophrenia: longitudinal analysis of the French FACE-SZ cohort","volume":"94","author":"Godin","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2019.04.021_bb0055","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2019.04.021_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psyneuen.2017.01.023","article-title":"Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial","volume":"78","author":"Jha","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2019.04.021_bb0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3346\/jkms.2008.23.2.193","article-title":"The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population","volume":"23","author":"Kim","year":"2008","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.schres.2019.04.021_bb0070","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.atherosclerosis.2007.12.053","article-title":"White blood cell count and the metabolic syndrome in older Chinese: the Guangzhou Biobank Cohort Study","volume":"201","author":"Lao","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.schres.2019.04.021_bb5005","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2019.04.021_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.04.021_bb0080","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antispychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2019.04.021_bb0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effect","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2019.04.021_bb0090","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","article-title":"Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects","volume":"73","author":"Miller","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.04.021_bb0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbi.2012.08.016","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses","volume":"31","author":"Miller","year":"2013","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.schres.2019.04.021_bb0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein levels in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2019.04.021_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbi.2014.12.005","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses","volume":"45","author":"Miller","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2019.04.021_bb5020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.schres.2019.04.021_bb0110","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","article-title":"Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis","volume":"41","author":"Mondelli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.04.021_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2015.10.001","article-title":"Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"169","author":"Mori","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.04.021_bb5015","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2169\/internalmedicine.50.5877","article-title":"Longitudinal study on white blood cell count and the incidence of metabolic syndrome","volume":"50","author":"Odagiri","year":"2011","journal-title":"Intern. Med."},{"key":"10.1016\/j.schres.2019.04.021_bb0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2019.04.021_bb5010","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2019.04.021_bb0125","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2019.04.021_bb0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","article-title":"Inflammation and clinical response to treatment in depression: a meta-analysis","volume":"25","author":"Strawbridge","year":"2015","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419301549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419301549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:31:58Z","timestamp":1760297518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419301549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"alternative-id":["S0920996419301549"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.04.021","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}